CytoSorbents Corporation                             Working to Save Lives                           Through Blood Purific...
Safe Harbor Statement   Statements in this presentation regarding CytoSorbents Corporation and its operating   subsidiary ...
CytoSorbents Overview      CytoSorbents is a publicly-traded critical care-focused    device company using blood purificat...
Recent Company Highlights • Achieved European CE Mark approval for CytoSorb™ as a first-in-class   extracorporeal cytokine...
Technology Overview                  The heart of the technology is a            biocompatible, highly porous, polymer bea...
Beads Can Be Used In Many Forms       Hemoperfusion   “Beads in a Bag”   In-line FilterCytoSorbents                       ...
CytoSorb Is Our Flagship Product                       ™          The cornerstone of our critical care strategy is        ...
Concept is Simple But Elegant The polymer beads are packed into cartridges compatible  with standard hemodialysis machines...
CytoSorb Approved For Sale in the E.U.                  ™       CytoSorb™ has received European regulatory approval       ...
Cytokines: A Dual-Edged Sword  • Cytokines are small proteins that, in moderation,    normally help stimulate and regulate...
Sepsis is a Worldwide Crisis     Sepsis is the result of an overzealous immune response           to infection, causing sy...
Sepsis has two facets but only one is treated The infectious insult can be treated with antibiotics/antivirals, but there ...
CytoSorb Designed to Fight Cytokine Storm      TOXIC         IN            SU               L   T                         ...
CytoSorb European Sepsis Trial                        ™   Completed a 43-patient randomized, controlled clinical trial    ...
These Patients Had a High Risk of Death               These risk factors are predictors of mortality• All had multiple org...
™          CytoSorb Treatment was Safe• No serious device related adverse events in more 300 treatments in  septic patient...
CytoSorb Broadly Reduces Cytokines                         ™  49.1%                                                       ...
™  CytoSorb Reduces 28 and 60-day Mortality in          Patients with High CytokinesIn patients with very high IL-6 (>1,00...
CytoSorb™ Reduces 14-day Mortality in                  Patients Age ≥ 65• CytoSorb™ treatment for 7 days shows  statistica...
CytoSorb Now Commercialized                       ™•   Focus is on direct sales in Germany•   Have begun a 3-6 month contr...
HemoDefend           Safeguarding the Quality and            Safety of the Blood Supply          HemoDefend is a technolog...
Transfusions Represents a Big Market• 15 million pRBCs transfused in the US alone each year  15 million more other blood p...
HemoDefend “Beads in a Bag” Platform• This is a highly innovative approach that  is unique to the characteristics of our  ...
Removes A Broad Range of Substances               Antibodies                    Bioactive Lipids                    Hemogl...
HemoDefend Can Be Transformative   HemoDefend converts a low margin blood storage bag into a  higher margin, self-containe...
CytoSorbents Has a Robust Pipeline                        With strong development capabilitiesNAME           INDICATION   ...
CytoSorbents Seeks Strategic Alliances  CytoSorbents has an active business development program      seeking partners for ...
CytoSorbents Seeks New Investors     CytoSorbents represents a major potential growth story• CytoSorb™ addresses the root ...
CytoSorbents Corporation          CytoSorbents Corporation          CytoSorbents                             Working to Sa...
Upcoming SlideShare
Loading in …5
×

CytoSorbents Corporation (OTCBB: CTSO) Investor Presentation, November 2011

1,810 views

Published on

CytoSorbents Corporation (OTCBB: CTSO) is a critical care-focused therapeutic device company using blood purification to treat life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and adsorption. In March 2011, CytoSorb™, the Company's flagship product, achieved European regulatory approval as an extracorporeal cytokine filter, and can now be sold throughout the European Union (E.U.) under the CE Mark to be used in cases where cytokines are elevated.

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,810
On SlideShare
0
From Embeds
0
Number of Embeds
537
Actions
Shares
0
Downloads
8
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

CytoSorbents Corporation (OTCBB: CTSO) Investor Presentation, November 2011

  1. 1. CytoSorbents Corporation Working to Save Lives Through Blood Purification CytoSorbents Investor Short Presentation November 2011 OTCBB: CTSOCytoSorbents
  2. 2. Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiary CytoSorbents, Inc that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. It is routine for our internal projections and expectations to change. Although these expectations may change, we are under no obligation to inform you if they do. Actual events or results may differ materially from those contained in the projections or forward-looking statements. The following factors, among others, could cause our actual results to differ materially from those described in a forward-looking statement: our history of losses; potential fluctuations in our quarterly and annual results; competition, inability to achieve regulatory approval for our device, technology systems beyond our control and technology-related defects that could affect the companies’ products or reputation; risks related to adverse business conditions; our dependence on key employees; competition for qualified personnel; the possible unavailability of financing as and if needed; and risks related to protecting our intellectual property rights or potential infringement of the intellectual property rights of third parties. This list is intended to identify only certain of the principal factors that could cause actual results to differ from those discussed in the forward-looking statements. Readers are referred to a discussion of important risk factors detailed in the Company’s Form 10-K filed with the Securities and Exchange Commission on May 31, 2011 and other reports and documents filed from time to time by us, which are available online at www.sec.gov.CytoSorbents 2
  3. 3. CytoSorbents Overview CytoSorbents is a publicly-traded critical care-focused device company using blood purification to treat disease, with its first European Union approved product, CytoSorb™CytoSorbents 3
  4. 4. Recent Company Highlights • Achieved European CE Mark approval for CytoSorb™ as a first-in-class extracorporeal cytokine filter, clinically proven in its European Sepsis Trial to reduce key cytokines by 30-50% in critically ill septic shock patients • In this trial, CytoSorb™ treatment also resulted in statistically significant improvement in mortality in patients at high risk of death from sepsis • Building CytoSorb™ inventory, manufactured under ISO 13485 Full Quality Systems certification • Limited-market release of CytoSorb™ in Germany began September 2011 with modest revenue expected year-end. Full launch: April 2012 • Reimbursement for CytoSorb™ has been established in Germany • Xigris, formerly the only treatment for sepsis, withdrawn from all marketsCytoSorbents 4
  5. 5. Technology Overview The heart of the technology is a biocompatible, highly porous, polymer bead that can remove a wide range of toxic substances from blood and fluids based on pore capture and surface adsorptionCytoSorbents 5
  6. 6. Beads Can Be Used In Many Forms Hemoperfusion “Beads in a Bag” In-line FilterCytoSorbents 6
  7. 7. CytoSorb Is Our Flagship Product ™ The cornerstone of our critical care strategy is CytoSorb ™ An efficient cytokine filter that can help fight “Cytokine Storm” and potentially reduce deadly inflammation and organ injuryCytoSorbents 7
  8. 8. Concept is Simple But Elegant The polymer beads are packed into cartridges compatible with standard hemodialysis machines or blood pumps • Obtain venous access with temporary dialysis catheter • Pump blood through the cartridge with standard pumps • The polymer beads remove cytokines • “Purified” blood is pumped back into the patient • Can treat 20-30 total blood volumes per 6 hr treatment • Each treatment uses a new cartridgeCytoSorbents 8
  9. 9. CytoSorb Approved For Sale in the E.U. ™ CytoSorb™ has received European regulatory approval under the CE Mark and can now be sold throughout the European Union as an Extracorporeal Cytokine Filter to be used whenever cytokines are elevatedCytoSorbents 9
  10. 10. Cytokines: A Dual-Edged Sword • Cytokines are small proteins that, in moderation, normally help stimulate and regulate the immune system. They are required for proper immune system function • However, in excess, cytokines can cause disease • But in life-threatening illnesses seen commonly in the ICU, they are produced in vast excess, often called “cytokine storm”, and can lead to cell death, organ damage, ultimately organ failure and deathCytoSorbents 10
  11. 11. Sepsis is a Worldwide Crisis Sepsis is the result of an overzealous immune response to infection, causing systemic inflammation • Top 10 killer afflicting 18 million people worldwide every year • Incidence of sepsis doubled in the past 10 years and is increasing • Severe sepsis kills 1 in every 3 despite the best medical treatment. Septic shock kills 1 in every 2 • Kills more people in the U.S. than either heart attacks, strokes, or any single type of cancer • Only approved product, Xigris, was just removed from all markets following its PROWESS SHOCK trial that showed no benefit in mortalityCytoSorbents 11
  12. 12. Sepsis has two facets but only one is treated The infectious insult can be treated with antibiotics/antivirals, but there are currently no therapies to treat the immune response and cytokine storm Cytokine Storm Pro-Inflammatory Anti-inflammatory TOXIC IN SU Death L T Organ Failure Recovery Time (days to weeks)CytoSorbents 12
  13. 13. CytoSorb Designed to Fight Cytokine Storm TOXIC IN SU L T Organ Damage Antibiotics CytoSorb Recovery TimeCytoSorbents 13
  14. 14. CytoSorb European Sepsis Trial ™ Completed a 43-patient randomized, controlled clinical trial to treat patients with severe sepsis or septic shock in the setting of acute respiratory distress syndrome/ALI• Compared standard of care therapy alone with standard of care therapy plus CytoSorb™ treatment (6 hours a day for 7 consecutive days)• Two goals of the trial • Demonstrate safety of treatment • Achieve statistical significance of primary endpoint of IL-6 reduction• Secondary and exploratory endpoints were included to examine effect on clinical endpoints like mortality and ventilator dependenceCytoSorbents 14
  15. 15. These Patients Had a High Risk of Death These risk factors are predictors of mortality• All had multiple organ failure • Nearly 100% had septic shock • 100% had respiratory failure with ~ 65% with Acute Respiratory Distress Syndrome (ARDS) • ~ 30% had Renal failure• Roughly half were Age ≥ 65 • Historically accounts for approximately two-thirds of all sepsis cases • Relative risk of death is 13-fold compared to younger population *• About one-third had extremely high cytokine levels: IL-6†, IL-1ra‡, MCP-1, IL-8 others * Martin GS, Crit Care Med 2006, 34(1):15-21 † Spittler A, Clin Infect Diseases, 2000, 31:1338-1342 ‡CytoSorbents Pablo R, J Intensive Care Med, 26(2):125-132 15
  16. 16. ™ CytoSorb Treatment was Safe• No serious device related adverse events in more 300 treatments in septic patients in the trial, increasing the total number of safely ™ administered human CytoSorb treatments to more than 650• Treatment was well-tolerated by patients• No clinically significant change in electrolytes or increase in markers of organ injury in nearly completed analysis• Small reduction in platelets and albumin, common to other extracorporeal therapies• Additional biochemical analysis and other marker removal is still underwayCytoSorbents 16
  17. 17. CytoSorb Broadly Reduces Cytokines ™ 49.1% 36.5%reduction reduction p=0.01* p=0.001 49.5% 30.2%reduction reduction p=0.002 p=0.002 Achieved statistically significant 30-50% reduction in key cytokines across the 7-day treatment period. Others are pendingCytoSorbents Electronic Randomization Only: N = 43 (18 treatment; 25 control) *interim/final analysis 17
  18. 18. ™ CytoSorb Reduces 28 and 60-day Mortality in Patients with High CytokinesIn patients with very high IL-6 (>1,000 pg/mL) or IL-1ra (>16,000 pg/mL) levels:• CytoSorb™ treatment shows statistically significant reduction in 28-day mortality (0% vs 63% control, p=0.03, n=14, 6 treated, 8 control)• Treatment also shows strong trend to benefit in reduction of 60-day mortality (17% vs 63% control, p=0.14, n=14)• Only 33% of treated patients required mechanical ventilator support at the end of 28-days, versus approximately 87% of control patients (p=0.09, n = 14)CytoSorbents 18
  19. 19. CytoSorb™ Reduces 14-day Mortality in Patients Age ≥ 65• CytoSorb™ treatment for 7 days shows statistically significant reduction in 14-day mortality (0.0% vs 36% control, p=0.05, n=21, 10 treated, 11 control)• 7 days of treatment was not enough to demonstrate 28-day mortality benefit (40% vs 45% control; p=0.6, n=21) suggesting that longer treatment in this very sick population is needed• Trend to benefit in: • Organ dysfunction as measured by MODS score, improved by 28% in treated patients vs 9% control (n=21) during the treatment period • Reduced ventilator need at 28-days (60% vs 73% control; n = 21)CytoSorbents 19
  20. 20. CytoSorb Now Commercialized ™• Focus is on direct sales in Germany• Have begun a 3-6 month controlled market release of CytoSorb™ in September 2011 in select areas in Germany, and plan a broader launch in Q2 2012• Expect modest revenue this year (2011)• Manufacturing under ISO 13485 is in full swing• Reimbursement for CytoSorb™ has been established in Germany• Plan to use independent distributors to penetrate rest of EuropeCytoSorbents 20
  21. 21. HemoDefend Safeguarding the Quality and Safety of the Blood Supply HemoDefend is a technology platform not yet approved in the US or EUCytoSorbents
  22. 22. Transfusions Represents a Big Market• 15 million pRBCs transfused in the US alone each year 15 million more other blood product transfusions• Rate of adverse reactions is 3-4%• Rate of TRALI is 1:2,000 to 5,000 with 10% deaths• Exact cause is unknown, but linked to accumulation of many substances during storage and degradation of blood cells, as well as donor factors • Antibodies • Cytokines and other inflammatory mediators • Bioactive lipids, free hemoglobin • Drugs, Foreign antigens• Ongoing concern that “old blood” is “bad blood” with increased risk of adverse events including cardiovascular deathCytoSorbents 22
  23. 23. HemoDefend “Beads in a Bag” Platform• This is a highly innovative approach that is unique to the characteristics of our highly biocompatible porous beads• Beads that remove different substances are placed into the bag during bag manufacturing• When blood is added, the neutrally buoyant beads distribute uniformly, preventing the need to mix the blood• Purification takes place during blood storage – a key to efficiency• A macrofilter prevents bead escape• No additional equipment is neededCytoSorbents 23
  24. 24. Removes A Broad Range of Substances Antibodies Bioactive Lipids Hemoglobin CytokinesCytoSorbents 24
  25. 25. HemoDefend Can Be Transformative HemoDefend converts a low margin blood storage bag into a higher margin, self-contained, “Blood Treatment System” that is both cost effective and easy to deployCytoSorbents 25
  26. 26. CytoSorbents Has a Robust Pipeline With strong development capabilitiesNAME INDICATION DESCRIPTION STATUSCytoSorb™ Severe sepsis and septic shock Highly efficient cytokine filter that is European CE Mark ARDS/ acute lung injury designed to treat cytokine storm and approved as a cytokine Burn and smoke inhalation injury inflammation filter in cases where Trauma cytokines are elevated Severe acute pancreatitis Complications of influenza Autoimmune disease flaresCytoSorb™ Cardiac Surgery Highly efficient cytokine filter to reduce Observational human cytokine-induced organ injury study completed Protection of organ transplants Human pilot study completedBetaSorb™ Improvement of hemodialysis in Removal of mid-molecular weight toxins Four human pilot studies end-stage renal disease that are inefficiently removed by standard completed dialysisHemoDefend Purification of blood transfusion “Beads in a Bag” purification technology Pre-clinical proof of products concept completedCST 101/201 Drug overdose/ Chemotherapy Efficient single pass removal of drugs and Pre-clinical proof of removal during high dose certain chemotherapy agents from blood concept completed regional chemotherapyCST 301 Trauma Removal of myoglobin from blood caused Pre-clinical proof of by muscle breakdown and concept completed rhabdomyolysis in traumaCytoSorbents 26
  27. 27. CytoSorbents Seeks Strategic Alliances CytoSorbents has an active business development program seeking partners for its growth technology portfolio Potential partners include companies involved in: • Dialysis and renal therapies • Pharmaceuticals • Critical care • Advanced materials • Blood purification Partnerships help validate the technology, provide resources to further develop products, are a source of non-dilutive funding, and are potential M&A candidatesCytoSorbents 27
  28. 28. CytoSorbents Seeks New Investors CytoSorbents represents a major potential growth story• CytoSorb™ addresses the root cause of why many patients die in the ICU from a wide range of critical illnesses• The total addressable market in critical care exceeds $10 billion• With approval of CytoSorb™, the company is transitioning for the first time in its history from a development-stage company to a revenue-based company with modest revenue expected in 2011• The company has a strong IP position with 29 issued patents• The pipeline for products continues to expand with HemoDefend and others, enabling the company to monetize its rich technology portfolio while pursuing core applications on its ownCytoSorbents 28
  29. 29. CytoSorbents Corporation CytoSorbents Corporation CytoSorbents Working to Save Lives Through Blood Purification OTCBB: CTSO Phillip P. Chan, MD, PhD CEO and President 7 Deer Park Drive, Suite K Monmouth Junction, NJ 08852 (732) 329-8885CytoSorbents pchan@cytosorbents.com

×